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Estrogen deficiency causes bone loss as a result of microdamage, oxida-
tive stress, and osteocyte apoptosis. A relationship between oxidative
stress-induced apoptosis, c-Jun N-terminal kinase (JNK) activation, and
expression of factors involved in bone remodeling has been demonstrated
in osteocytes. However, the molecular regulation of these events in osteo-
cytes treated with 17b-estradiol (17b-E2) remains unexplored. The MLO-
Y4 murine osteocyte-like cell line was used as a model to study starva-
tion-induced apoptosis and ROS production during 17b-E2 treatment.
Expression of glutathione S-transferase P1-1 (GSTP1-1), receptor activa-
tor kB ligand (RANKL), osteoprotegerin (OPG), sclerostin, and kinases
activation were measured by western blot. In addition, the GSTP1-1/JNK
association was assessed by immunoprecipitation, and GSTP1-1 involve-
ment in the osteocyte response to 17b-E2 was detected by specific siRNA
transfection. 17b-E2 prevents starvation-induced apoptosis (DNA frag-
mentation and caspase activation), the increase in sclerostin expression
and the RANKL/OPG ratio, which are all related to JNK activation due
to oxidative stress in osteocytes. This occurs through GSTP1-1 overex-
pression, which can inhibit JNK activation by formation of a GSTP1-1/
JNK complex. No early antioxidant action of 17b-E2 has been found but
the estrogen effect is similar to N-acetylcysteine which, by increasing the
intracellular redox state, maintains JNK bound to GSTP1-1. Thus, the
antiapoptotic and osteogenic effect of 17b-E2 in MLO-Y4 occurs by a
redox-independent process involving GSTP1-1/JNK association. This
study clarifies at molecular level the effect of 17b-E2 on osteocyte activity
and identifies a possible role of GSTP1-1 and JNK activity in bone
remodeling and repair mechanisms.
Estrogens influence the size and shape of the skeleton
during growth and contribute to bone homeostasis
during adulthood. The decline in estrogen levels,
associated with menopause, causes bone loss in women
related to a high rate of bone remodeling [1,2] which
results from the close balance between osteoblast and
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osteoclast activity, leading to either bone formation or
bone resorption, respectively. Recently, new data sup-
port the central regulatory role of osteocytes in the
maintenance of this balance and thus in viability and
functionality of bone [3,4]. Estrogen deficiency alters
osteoblast mineralization and osteoclast resorption
activity, leading to increased bone resorption and
osteoporotic cascade [1,2,5]. In fact, estrogens, through
their receptors, increase bone mineralization [1,2,6,7],
whereas estrogen deficiency causes an increase in
osteoblast and osteocyte apoptosis in both the trabecu-
lar and cortical compartment [1]. This causes a
deteriorated microarchitecture and reduced mechanical
strength of bone as well as increased fracture risk [1,8].
The marked reduction in estrogen induces oxidative
stress related to menopause and bone loss [9–12]. In
fact, it has been demonstrated that, in addition to
aging, ovariectomy induces oxidative stress in rat
femurs along with decreased activity of antioxidant
systems [12]. Moreover, the protective effects of estro-
gens on bone result from their ability to attenuate
oxidative stress [13] by activating antioxidant gene
expression [9–11,13] or by a direct free radical scaveng-
ing activity [14]. However, other data indicate that
estrogen therapy has no significant effect on oxidative
stress levels [11,15].
Many studies, performed on osteoblasts and osteo-
clasts, have linked reactive oxygen species (ROS) and
antioxidants to bone metabolism and bone remodel-
ing [13,16–18]. In osteocytes, high levels of ROS
induce increased apoptosis [14,19–21], and this is also
related to loss of estrogens and a decrease in bone
mineral density [12,22,23], as occurs in aging and
chronic glucocorticoid treatment [12,19,22,24–27].
Since osteocytes are mechanosensitive cells [3,4],
increased apoptosis may impair the ability of bone to
adaptively respond to mechanical loading and to
repair microdamage due to physiological or patholog-
ical events such as aging, osteoporosis, or osteoarthri-
tis, also related to oxidative stress [3,19,22–26]. It has
been demonstrated that the modulation of mechanical
loading and ovariectomy induce an increase in osteo-
cyte apoptosis and lead to microdamage [19,22,23]
with subsequent osteoclastic invasion to the damaged
site and activation of the remodeling process [28–31].
Estrogen treatment prevents osteoblast and osteocyte
apoptosis [1,2,5,13,14,23], although molecular mecha-
nisms and biochemical signals, by which estrogens
protect osteocytes from the apoptosis due to micro-
damage and/or oxidative stress, have not been fully
elucidated. Similarly, to our knowledge in osteocytes,
no data are reported on the molecular processes by
which estrogens modulate the expression of cytokines
involved in bone remodeling in the presence of oxida-
tive stress-induced apoptosis.
The aim of this study was to investigate the molecu-
lar processes by which 17b-Estradiol (17b-E2) prevents
osteocyte apoptosis and the abnormal expression and
release of factors related to increased oxidative state
and bone remodeling. The effect of 17b-E2 on ROS
production and the activation of redox-regulated
kinases, such as extracellular signal-regulated kinase
(ERK1/2) and c-Jun N-terminal kinase (JNK), were
also studied. Indeed, in osteocytes, these kinases are
involved in oxidative stress-induced apoptosis and
expression of receptor activator kB ligand (RANKL),
osteoprotegerin (OPG), and sclerostin [21]. To clarify
the molecular action of estrogen on these events, the
role of mitogen-activated protein kinase phosphatase-1
(MKP-1) and glutathione S-transferase P1-1 (GSTP1-
1), both involved in the regulation of JNK activity,
were investigated [32–35]. This study was performed in
MLO-Y4, a murine osteocyte-like cell line, that consti-
tutes an in vitro model for studying osteocyte viability
and apoptosis in response to microdamage and bone
diseases [31,36–38]. Apoptosis due to oxidative stress
was induced in MLO-Y4 by serum starvation [21].
This method causes apoptosis not due to proinflamma-
tory and proapoptotic factors and mimics in vitro a
metabolic condition of oxidative stress that may be
similar to what occurs in vivo in the bone environment
after microdamage [19,20,31,37–39]. In fact, apoptosis
due to microdamage may be related to a disruption of
blood and fluid flow with consequent lack of various
endocrine factors, including estrogens [31,40,41]. Thus,
it is possible to investigate “in vitro” the regulatory
role of estrogens in osteocyte apoptosis in bone
remodeling.
Materials and methods
MLO-4Y culture and treatment
MLO-4Y (a gift from L. Bonewald, University of Mis-
souri-Kansas City) were cultured at 37 °C in a 5% CO2
humidified atmosphere in alpha-MEM medium supple-
mented with 5% calf serum (GE Healthcare HyClone, Lit-
tle Chalfont, UK), 5% FBS (HyClone), 2 mM L-glutamine,
72 mgL1 (L)-penicillin, and 100 mgmL1 (L)-streptomy-
cin (complete medium). Cells at 70–80% confluence were
treated for 30 min in a medium, in which FBS was
substituted with charcoal stripped FBS (Sigma-Aldrich,
Saint Louis, MO, USA), with 17-b-E2 (Sigma-Aldrich) at
various concentrations (1, 10 or 100 nM), or in complete
medium in the absence (untreated cells) or in the presence
of 5 mM N-acetylcysteine (NAC, Sigma-Aldrich) for 16 h.
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Subsequently, after removal of the media, treated cells were
cultured for another 4 or 24 h in serum free medium in the
presence of 17-b-E2 or NAC. Untreated cells were cultured
for 4 or 24 h in serum free medium (S, starved cells) or in
fresh complete medium (C, control). 0.01% ethanol (vehicle
for estrogen) was added to all untreated 17-b-E2 cells. For
experiments with inhibitors, cells were pretreated for 30 min
in complete medium with 1 lM diphenyleneiodonium
(DPI) or 100 lM 4-(2-aminoethyl)-benzenesulfonylfluoride
(AEBSF) or 5 nM 2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-
ylamino)-2-oxoethyl-triphenylphosphonium chloride mono-
hydrate (Mito TEMPO), (Sigma-Aldrich) in the presence
or in the absence of estrogen. Subsequently, the complete
medium was removed and for another 4 or 24 h, cells were
cultured with inhibitors with or without estrogen in serum-
free medium. In experiments with DPI, 0.003% DMSO
was added to DPI untreated cells. Some treatments were
performed in cells transiently transfected with 60 nM
mouse GSTP1-1 siRNA corresponding to two DNA target
sequences of mouse GSTP1-1 (50-CCCUCAUCUACA
CCAACUA[dT][dT]-30); 50-UAGUUGGUGUAGAUGAG
GG[dT][dT]-30) (Sigma) or scrambled siRNA (scr siRNA)
(Universal Negative Control #1, Sigma), using lipofec-
tamine RNAiMAXTM (Invitrogen Carlsbad, CA, USA)
according to the manufacturer’s protocol. The ability of
siRNA to silence the expression level of GSTP1-1 mRNA
was checked 24 h after transfection.
Measurement of MLO-4Y apoptosis
MLO-4Y seeded in six-well plates and treated with 17-b-
E2 as above reported were used to assess apoptosis using
the Cell Death Detection ELISA plus Kit (Roche Labo-
ratories, Nutley, NJ, USA), according to the manufac-
turer’s instructions. The apoptosis assay was performed
measuring the specific increase in mono- and oligonucleo-
somes released into the cytoplasmic fractions obtained
from 104 cells using the following formula: fold-
increases = absorbance of the samples/absorbance of the
corresponding controls (C).
Measurement of intracellular ROS
The intracellular ROS production was measured in
MLO-4Y seeded in six-well plates and treated as above
reported. One hour before the end of treatments, 20,70-
dichlorodihydrofluorescein diacetate (H2DCFDA, Invitro-
gen) was added to culture medium. After PBS washing,
cells were lysed in RIPA buffer (50 mM Tris/HCL pH
7.5, 1% Triton X-100, 150 mM NaCl, 100 mM NaF,
2 mM EGTA; Sigma-Aldrich), centrifuged at 11 600 g for
10 min, and analyzed immediately by fluorescence spec-
trophotometric analysis at 510 nm. Data, normalized on
total protein content, were expressed as fold-increase over
the control values.
Western blot analysis
The phosphorylation of ERK1/2 and JNK, the activation
of caspase-3 and the expression of RANKL, OPG, scle-
rostin, GSTP1-1, and MKP-1 were performed by western
blot in MLO-4Y treated as above reported. Cells were
lysed in ice cold RIPA buffer containing phosphatase
and protease inhibitor cocktails (Sigma) and centrifuged
at 11 600 g for 10 min. Equal amounts of total proteins
(40–60 lg) from whole-cell extract were subjected under
reducing conditions to SDS/PAGE on 10% gel and elec-
trotransferred to PVDF membrane (GE Healthcare). Pro-
teins were visualized by incubating the membranes with
specific primary antibodies: anti-caspase 3 or anti-phos-
pho-ERK 1/2 or anti-phospho-JNK (Cell Signalling
Technology, Beverly, MA, USA), or anti-RANKL or
anti-OPG or anti-sclerostin or anti-GSTP1-1 or anti-
MKP-1 (Santa Cruz Biotechnology, Inc., Dallas, TX,
USA). Subsequently, membranes were stripped and
reprobed with anti-ERK1/2 or anti-JNK or anti-b-actin
for normalization and densitometric analysis. Secondary
antibodies conjugated to horseradish peroxidase were
used to detect antigen–antibody complexes with a chemi-
luminescence reagent kit (Bio-Rad, Hercules, CA, USA).
IMAGE J software (National Institutes of Health,
Bethesda, MD, USA) was used to perform quantitative
analyses, and band values were expressed as percentage
relative to values of control.
Immunoprecipitation and immunoblot
Immunoprecipitation was carried out using 2 lg of anti-
GSTP1-1 or anti-JNK antibody or negative control mouse
IgG (BIOCARE Medical, Pacheco, CA, USA) and 400 lg
of total protein lysates, for 16 h at 4 °C. Subsequently,
protein A/G PLUS-Agarose Immunoprecipitation Reagent
(Santa Cruz Biotechnology, Inc.) was added (20 lL) for
1 h at 4–5 °C, after which washes were carried out in PBS
supplemented with Tween-100 (0.5%). Precipitate was sus-
pended in sample buffer without b-mercaptoethanol (nonre-
ducing conditions) and was subjected to SDS/PAGE (10%)
followed by electrotransfer to PVDF membrane. Reaction
with the anti-JNK or anti-GSTP1-1 overnight at 4 °C was
carried out. Subsequently to stripping, membranes were
reprobed with anti-GSTP1-1 or anti-JNK or anti b–Actin.
Measurement of RANKL and OPG release
Receptor activator kB ligand and OPG release was mea-
sured in the culture medium of MLO-Y4 treated as above
reported, using quantitative sandwich enzyme immunoassay
kits (R&D System, Minneapolis, MN, USA) according to
the manufacturer’s instructions. Data, normalized on total
protein content, were expressed as fold-increase over the
control values.
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Protein assay
Protein concentrations were determined by the bicin-
choninic acid solution protein reagent assay (Pierce, Rock-
ford, IL, USA) using bovine serum albumin as the
standard (Sigma-Aldrich).
Statistical analysis
All experiments were performed four times in triplicate.
Data were expressed as mean  SEM and statistical signifi-
cance of the differences was determined by Student’s t-test.
P ≤ 0.05 was considered statistically significant.
Results
Effect of 17 b-E2 on apoptosis and ROS
production in starved MLO-Y4 cells
Figure 1A shows that apoptosis increased remarkably
after 4 and 24 h from the starvation, and the pretreat-
ment of MLO-4Y for 30 min with various concentra-
tions of 17 b-E2 reduced starvation-induced apoptosis
at both times, as compared to the respective untreated
starved cells. Under the experimental conditions in this
study, the maximum effect of apoptosis inhibition
(about 60%) was measured at 10 nM 17 b-E2, a con-
centration near physiological value and used in the
subsequent treatments. No statistically different change
between 10 nM and 100 nM 17 b-E2 was measured.
The antiapoptotic effect of 10 nM 17 b-E2 was con-
firmed by the decrease of caspase-3 active form
involved in the apoptosis of osteocytes. In fact, estro-
gen significantly decreased—by about 50–60%—active
17 kDa caspase-3, that derives from proteolytic cleav-
age of inactive 32-kDa procaspase-3 [14,21,42]
(Fig. 1B). Figure 2 shows that the levels of ROS
increased after 4 and 24 h from the starvation, and 17
b-E2 lowered ROS content partially (about 30%) only
after 24 h, as compared to untreated starved cells.
Subsequently, 17 b-E2 effect on ROS and apoptosis
was compared with that obtained in cells treated with:
DPI or AEBSF, inhibitors of NADPH oxidase activ-
ity; Mito TEMPO, a specific scavenger of mitochon-
drial ROS; or NAC, a direct antioxidant [14,21,43–45]
(Fig. 2A,B). The inhibitors were used at concentra-
tions able to inhibit ROS production. Under our
experimental conditions, AEBSF and DPI, similarly to
17 b-E2, significantly reduced ROS levels by about
40% only after 24 h; conversely, Mito TEMPO signifi-
cantly inhibited ROS levels by about 50–60% at both
times, similarly to NAC (Fig. 2A). Figure 2B reports
the apoptosis levels measured in cells treated with
inhibitors and stimulated or not by 17 b-E2; no change
in apoptosis was observed in DPI- and AEBSF-treated
cells at either studied time and no synergic effect was
detected in cells treated with these inhibitors plus
estrogen. Mito TEMPO and NAC decreased apoptosis
levels by about 60% as compared with starved cells
stimulated or not with estrogen (Fig. 2B).
Fig. 1. Effect of various concentrations of 17b-E2 on apoptosis and
active 17 KDa caspase-3 in MLO-Y4 cells. Apoptosis (A) and active
17 KDa caspase-3 (B) were measured in MLO-Y4 cells cultured for
4 h and 24 h in complete medium (C, control) or in serum-free
medium (S, starved cells). S were treated or not with 17b-E2 as
reported in Materials and methods. Apoptosis data, relative to
mono- and oligonucleosomes released into the cytoplasmic fraction
from 104 cells treated with various nM concentrations of 17b-E2,
are expressed as fold-increase over the respective C values and
are the mean  SEM of four experiments. Active 17 KDa caspase-
3 was measured in cells treated with 10 nM 17b-E2 by Western
blot analysis. Blots are representative of four experiments and the
active 17 kDa caspase-3 values are normalized with b-Actin bands
obtained by densitometric analysis and reported as the mean
percentage  SEM relative to the respective C values in the
bottom. *P ≤ 0.05 and **P ≤ 0.005 compared to the respective S
values; °P ≤ 0.005 compared to the respective C values.
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Effect of 17 b-E2 on ERK1/2 and JNK activation
and MKP-1 expression in starved MLO-Y4 cells
Figure 3 shows that both ERK1/2 and JNK phosphoryla-
tion increased after 4 h and 24 h from starvation, and 17
b-E2 inhibited JNK activation at both times by about
60–70%, as compared with unstimulated starved cells
(Fig. 3B); no significant effect of 17 b-E2 on ERK1/2 acti-
vation was observed (Fig. 3A). Previously, we related star-
vation-induced apoptosis to JNK activation [21], therefore,
in order to clarify the involvement of JNK inhibition on 17
b-E2 antiapoptotic effect, the expression of MKP-1, a speci-
fic phosphatase for JNK [32,33], was investigated. Fig-
ure 3C shows no change in MKP-1 expression at both
times in 17 b-E2 cells, stimulated or not.
Effect of 17 b-E2 and NAC on JNK association
with monomeric GSTP1-1 form and GSTP1-1
expression in starved MLO-Y4 cells
Previous data demonstrated that GSTP1-1 monomeric
form binds JNK, inhibiting its activation, and the ability
of GSTP1-1 to bound JNK is related to oxidative state
and/or to GSTP1-1 expression level [34,35,46,47]. In
Fig. 4A no band of JNK or GSTP1-1 or b-Actin was
detected in Western blot analysis of immunoprecipitates
performed with IgG (negative control) in control cells.
Differently, JNK and GSTP1-1 bands and no b-Actin
were detected after immunoprecipitation with anti-
GSTP1-1 or anti-JNK antibody (Fig. 4A). These data
demonstrate the absence of non-specific bands under
these experimental conditions. Figure 4B shows JNK
bands obtained by western blot analysis under nonreduc-
ing SDS/PAGE of immunoprecipitates performed with
anti-GSTP1-1 antibody; a decrease in JNK associated
with monomeric GSTP1-1 form (26 kD) was registered
only in starved cells as compared with control. On the
contrary, both 17 b-E2 and NAC treatments prevented
this dissociation after 4 and 24 h, and the band density of
JNK was similar to those of controls (Fig. 4B). The strip-
ping and reprobing of the same blots by anti-GSTP1-1
antibody show that the band density of GSTP1-1 mono-
meric form changed similarly to that of JNK bands
(Fig. 4B). The same results with regard to the association
of monomeric form of GSTP1-1 with JNK were obtained
by JNK immunoprecipitation experiments performed
under nonreducing SDS/PAGE (Fig. 4C).
To evaluate the expression of total GSTP1-1 in 17
b-E2- and NAC-treated cells, western blot analysis of
cellular lysates in reducing conditions was performed
(Fig. 4D). A significant increase in total GSTP1-1
expression in estrogen-treated cells, as compared to
control, was measured but no variation was noted in
starved and NAC-treated cells.
Fig. 2. Effect of 17b-E2, DPI, AEBSF, Mito
Tempo and NAC on intracellular ROS and
apoptosis in MLO-Y4 cells. Intracellular
ROS (A) and apoptosis (B) were measured
in MLO-Y4 cells cultured for 4 and 24 h in
complete medium (C, control) or in serum-
free medium (S, starved cells). S were
treated or not with 10 nM 17b-E2, 1 lM
DPI, 100 lM AEBSF, 5 nM Mito-TEMPO,
or 5 mM NAC as reported in Materials and
methods. ROS data, normalized on total
protein content, and apoptosis data,
relative to mono- and oligonucleosomes
released into the cytoplasmic fraction from
104 cells, are expressed as fold-increase
over the respective C values. The data are
the mean  SEM of four independent
experiments. *P ≤ 0.05 and **P ≤ 0.005
compared to the respective S values.
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Role of GSTP1 in 17 b-E2 and NAC effect on
apoptosis and JNK activation in starved MLO-Y4
cells
Figure 5A shows that GSTP1-1 expression decreased
in control cells transfected with specific siRNA after
24 h of transfection. Figure 5B shows that the down-
regulation of GSTP1-1 induced a significant increase
in apoptosis in starved cells treated with NAC or 17
b-E2 at both studied times, as compared to the respec-
tive scr siRNA-starved cell values (Fig. 5B). In partic-
ular, down-regulation of GSTP1-1 in 17 b-E2-treated
cells reverted the apoptosis and JNK activation levels
to the values measured in untreated scr siRNA starved
cells (Fig. 5B–D). In NAC-treated cells, down-regula-
tion of GSTP1-1 increased also apoptosis and JNK
activation levels, but these did not reach the levels of
untreated scr siRNA starved cell, even if the changes
in JNK activation were not significant as compared
with untreated scr siRNA-starved cells (Fig. 5B–D).
Figure 6 summarizes the possible effects of 17 b-E2
and NAC on the association of JNK to GSTP1-1 in
relation to JNK and apoptosis activation in starved
MLO-4Y cells.
Effect of 17 b-E2 on expression and release of
RANKL and OPG, and on Sclerostin expression in
starved MLO-Y4 cells
The expression of RANKL, OPG, and sclerostin was
determined in starved MLO-4Y cells treated with 17 b-
E2, considering that in these cells a relationship among
apoptosis, increased oxidative state, and expression of
these factors has been previously found [21]. In particu-
lar, in the cited study, in starved MLO-Y4 cells oxidative
stress-induced activation of JNK and ERK1/2 and this
was related to RANKL and sclerostin up-regulation,
whereas only JNK activation was involved in decreased
OPG levels [21]. Figure 7A,B shows, after 4 or 24 h of
starvation, a significant increase in RANKL and scle-
rostin levels, as compared with control, and 17 b-E2
treatment decreased them by about 50%-60%, but levels
did not return to those of controls. On the contrary,
OPG remarkably decreased at both starvation times, as
compared with control cells, and 17 b-E2 inhibited by
about 50% the reduction of OPG expression only after
24 h of starvation (Fig. 7C). Also, in this case estrogen
was not able to revert OPG levels to the control value
(Fig. 7C). Figure 7D shows that 17 b-E2 treatment sig-
nificantly lowered RANKL release after 24 h of starva-
tion as compared with untreated and starved cells.
However, 17 b-E2 did not restore RANKL release to
control values in accordance to that observed on
RANKL expression. Similar results were obtained after
4 h of starvation (data not shown). Regarding OPG pro-
tein release, we were not able to measure the levels of this
protein by ELISA kit in MLO-Y4 in agreement with
results previously reported by us and others [21,31]. For
this reason, the RANKL/OPG ratio was measured by
Fig. 3. Effect of 17b-E2 on MAPKs phosphorylation and MKP-1
expression in MLO-4Y cells. Phosphorylation of ERK1/2 (A) and
JNK (B) and MKP-1 expression (C) were detected by western blot
analysis in MLO-Y4 cells cultured for 4 or 24 h in complete
medium (C, control) or in serum-free medium (S, starved cells). S
were treated or not with 10 nM 17b-E2 as reported in Materials
and methods. Blots are representative of four experiments and the
values are normalized with ERK1/2 or JNK bands obtained by
densitometric analysis and reported as mean percentage  SEM
relative to the respective C values in the bottom. *P ≤ 0.05
compared to the respective C values; ○P ≤ 0.05 as compared to
the respective S values.
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the expression values obtained in western blot analysis
(Fig. 7A,C). The ratio increased in a similar manner after
4 h and 24 h of starvation as compared with control cells
(Fig. 7E), and 17 b-E2 significantly lowered the ratio val-
ues at both times by about 40–70%, respectively
(Fig. 7E). The decrease in ratio value after 24 h of starva-
tion was significantly higher than that obtained after 4 h.
Discussion
This study provides new evidence that 17b-E2 in
starved MLO-Y4 quickly reduces apoptosis and the
related caspase-3 activation due to increased oxidative
state, without significant inhibition of ROS produc-
tion. Under the same experimental conditions, 17b-E2
prevents the increase in RANKL and sclerostin expres-
sion, RANKL release, and RANKL/OPG ratio. For
the first time, these effects of 17b-E2 are shown to
occur by a redox-independent process of JNK activa-
tion involving GSTP1-1 overexpression. The ability of
17b-E2 to prevent starvation-induced apoptosis is simi-
lar to that obtained in MLO-Y4 after treatment with
the antioxidants [21], indeed, we previously demon-
strated a redox-regulated osteocyte apoptosis due to
Fig. 4. Effect of 17b-E2 and NAC on JNK
association with monomeric GSTP1-1 form
and GSTP1-1 expression in MLO-4Y cells.
JNK association with GSTP1-1 and GSTP1-
1 expression were detected in MLO-Y4
cells cultured for 4 or 24 h in complete
medium (C, control) or in serum-free
medium (S, starved cells). S were treated
or not with 10 nM 17b-E2 or 5 mM NAC as
reported in Materials and methods. The
negative control was performed in MLO-
Y4 cells cultured for 24 h in complete
medium by immunoprecipitation with
negative control mouse IgG (A). For
detection of JNK bound to-GSTP1-1 or IgG
(A and B), or GSTP1-1 bound to JNK or
IgG (A and C), or bActin bound to IgG (A)
all immunoprecipitates of equal proteins
(400 lg) were performed using anti-
GSTP1-1 antibody or anti-JNK antibody or
IgG respectively, as reported in Materials
and Methods. Western blot analyses were
performed under non-reducing conditions
(without b-mercaptoethanol) and
membranes were probed with anti-JNK (A
and B) or anti GSTP1-1 (C) antibodies and
subsequently, after stripping, with anti-
GSTP1-1 (A and B) or anti-JNK (C) or anti-
bActin (A) antibodies, respectively. GSTP1-
1 expression (D) was detected by
Western blot analysis performed under
reducing condition. The normalized values
with b-Actin bands obtained by
densitometric analysis are reported as
mean percentage  SEM relative to the
respective C values in the bottom. The
blots are representative of four
experiments. *P ≤ 0.05 compared to the
respective C values.
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starvation. However, our data in MLO-Y4 demon-
strate that 17b-E2 significantly decreases starvation-
induced apoptosis and caspase-3 activation at both the
studied times, but only after 24 h from the starvation
does 17b-E2 show a weak antioxidant action. On the
contrary, NAC, a direct ROS scavenger, remarkably
reduces ROS levels at both times, and this has previ-
ously been related to its ability to prevent starvation-
induced osteocyte apoptosis [21]. Some authors
demonstrate that the antiapoptotic effect of estrogen is
due to its action as direct ROS scavenger [14] and
others indicate 17b-E2 as inhibitor of NADPH oxidase
[43]. However, our findings do not show a relationship
between the antiapoptotic effect of 17b-E2 and its
antioxidant action, which seems to be weak, late, and
caused by the inhibition of NADPH oxidase activity, a
membrane enzyme which increases cytoplasmic oxida-
tive state [44]. Diversely, in starved osteocytes the
increased ROS levels and consequent apoptosis at both
times seem to be mainly of mitochondrial origin, and
this agrees with previous data which show in MLO-Y4
the involvement of JNK activation [21]. Indeed, JNK
activity prevalently mediates stress-induced apoptosis
by mitochondrial pathways [48], and this may occur in
osteocytes through increased permeability of the outer
mitochondrial membrane with the release of cyto-
chrome C-activating caspases (caspase-3,-6, and -7)
responsible for cell death [19].
Effectively, it seems difficult for estrogen to have a
direct antioxidant effect as shown by others who
induced apoptosis by extracellular H2O2 treatment in
MLO-Y4 cells [14]. In fact, in this study, the estrogen
was used at a much lower concentration (10 nM) than
that of H2O2 (0.3 mM). Also “in vivo” it is unlikely
that estrogens may have a direct antioxidant effect
given that their circulating levels are lower than the
concentrations of chemical antioxidants necessary to
reduce the oxidative stress [9,49]. Indeed, “in vitro”
Fig. 5. Effect of GSTP1-1 siRNA on
apoptosis and JNK phosphorylation in 17b-
E2 or NAC treated MLO-4Y cells. MLO-Y4
cells, transfected with GSTP1-1 siRNA or
scr siRNA (negative control) for 24 h, were
cultured for 4 or 24 h in complete medium
(C, control) or in serum-free medium (S,
starved cells). Transfected S were treated
or not with 10 nM 17 b -E2 or 5 mM NAC
as reported in Materials and methods.
GSTP1-1 expression (A) and JNK
phosphorylation after 4 h (C) or 24 h (D)
were detected by western blot analysis.
The blots are representative of three
experiments and the normalized values
with JNK bands obtained by densitometric
analysis are reported as mean
percentage  SEM relative to the
respective C values. Apoptosis data (B),
relative to mono- and oligonucleosomes
released into the cytoplasmic fraction from
104 cells, are expressed as fold-increase
over C values, and are the mean  SEM
of three independent experiments.
*P ≤ 0.05 compared to the respective scr
siRNA-treated cell values. ○P ≤ 0.05
compared to scr siRNA S values.
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and “in vivo” studies demonstrate that 17b-E2 antioxi-
dant action is related to an up-regulation of antioxi-
dant enzymes [9,11–13,49]. However, this mechanism
may require longer than a direct antioxidant action,
and our data suggest that the early antiapoptotic effect
of 17b-E2 occurs in the presence of an oxidative state.
As previously reported, JNK and ERK1/2 are acti-
vated by an increased oxidative status in starvation-
induced osteocyte apoptosis [21]. However, it has been
demonstrated that only JNK activity is involved in
oxidative stress-induced apoptosis in MLO-Y4, and
that the antioxidants including NAC are able to inhi-
bit both JNK and ERK1/2 activity by decreasing ROS
levels [21]. Similarly to antioxidants, 17b-E2 inhibits
JNK activation in starved MLO-Y4 cells at both stud-
ied times, and this can be related to the antiapoptotic
effect of 17b-E2, but not to decreased ROS levels. This
indicates that 17b-E2 antiapoptotic effect occurs
through a process which is unrelated to oxidative sta-
tus. Moreover, 17b-E2 does not affect ERK1/2 activa-
tion due to the presence of the oxidative status,
indicating that ERK1/2 activation is not involved in
the 17b-E2 protective effect against osteocyte apopto-
sis, similarly to that observed by others in osteocyte
apoptosis induced by H2O2 treatment [14].
No data are reported in literature on a protective
effect of 17b-E2 on oxidative stress-induced apoptosis
in osteocytes by down-regulation of JNK activity. For
this purpose, we studied the role of MKP-1, a member
of the MKP family that predominately dephosphory-
lates JNK [32,33], in estrogen-induced JNK inactiva-
tion. Indeed, through its receptors 17b-E2 can induce
genomic expression of MKP-1 in various cells includ-
ing bone cells [32], and it has been shown that MKP-
1-modulated JNK activity is critical for apoptosis
induced by the inhibition of epidermal growth factor
receptor tyrosine kinase in lung cancer cells [32]. We
demonstrated that MKP-1 is expressed in osteocytes
but, under the studied experimental conditions, 17b-E2
and the increased oxidative state do not induce an
overexpression of this phosphatase, excluding its possi-
ble role in JNK inactivation by estrogen.
Our findings demonstrate, for the first time, that
GSTP1-1, a detoxifying enzyme also involved in cell
death and/or survival mechanisms, is expressed in
osteocytes and is related to the antiapoptotic effect of
17b-E2 mediated by JNK inactivation in the presence
of oxidative state. In fact, it is well demonstrated that
GSTP1-1 is a regulator of JNK signaling pathways
through the formation of a complex with c-Jun-JNK.
This association occurs with GSTP1-1 monomeric
form and selectively inhibits the phosphorylation and
activation of JNK [34,35,46,47,50]. The present work
demonstrates that, under normal physiological condi-
tions, GSTP1-1 monomeric form is in reversible equi-
librium with dimeric and polymeric forms and that
this balance shifts, in the presence of oxidative state,
versus polymeric forms due to the formation of disul-
fide bonds [47,48,50], inducing GSTP1-1/JNK dissocia-
tion and apoptosis activation [34,35,46,47]. In
agreement with literature data, immunoprecipitation
and immunoblot experiments demonstrate that in
MLO-4Y cells JNK is bound to GSTP1-1 and under
conditions of oxidative stress both the levels of bound
Fig. 6. Summary of 17b-E2 and NAC
different mechanisms on JNK-GSTP1-1
complex formation in starved MLO-Y4
cells. NAC and 17b-E2 reduce JNK-GSTP1-
1 complex dissociation- and starvation-
induced apoptosis favoring JNK/GSTP1-1
complex association by ROS decrease and
GSTP1-1 expression increase,
respectively. [+] = increase; [] = decrease
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JNK and GSTP1-1 monomeric form decrease in
starved cells. This is inversely related to JNK activa-
tion which increases only when there are high levels of
ROS, suggesting GSTP1-1/JNK dissociation. This
redox regulation of GSTP1-1/JNK complex formation
is confirmed by findings obtained with NAC treat-
ment. In fact, NAC preserves JNK bound levels, pre-
venting complex dissociation and JNK activation. This
could be due to the ability of NAC to preserve high
levels of GSTP1-1 monomeric form through the lower-
ing of ROS levels and the breaking of disulfide bonds
present in GSTP1-1 oligomeric forms.
Our data show that 17b-E2 is also able to maintain
high levels of both GSTP1-1 monomeric form and
JNK linked to GSTP1-1. This indicates that estrogen
may preserve GSTP1-1/JNK complex dissociation with
the consequent JNK inactivation even if an oxidative
state is present. The effect of 17b-E2 can be related to
the overexpression of GSTP1-1, which is consistent
with data showing that the overexpression of GSTP1-1
can affect the balance between the various forms of
GSTP1-1 and the possible bond with JNK
[34,35,46,47,51]. Indeed, the increased GSTP1-1 expres-
sion can promote the formation of the GSTP1-1/JNK
complex by counteracting the action of ROS which, dif-
ferently, induces complex dissociation and JNK activa-
tion. This has been demonstrated by other researchers
who have correlated it to apoptosis resistance of tumor
cells [34,46,47]. In agreement with our data, Bartolini
et al. [51] report that GSTP1-1 overexpression inhibits
stress-induced JNK activation, whereas it does not
affect ERK1/2 activation.
Fig. 7. Effect of 17b-E2 on RANKL, sclerostin, and OPG expression and RANKL release in MLO-Y4 cells. RANKL, sclerostin, and OPG
expression and RANKL release were measured in MLO-Y4 cells cultured for 4 or 24 h in complete medium (C, control) or in serum-free
medium (S, starved cells). S were treated or not with 10 nM 17b-E2 as reported in Materials and methods. RANKL (A), sclerostin (B), and
OPG (C) were measured by western blot analyses of cell lysates. Blots are representative of four experiments and the normalized values
with b-Actin bands obtained by densitometric analysis are reported as mean percentage  SEM relative to the respective C values. RANKL
release (D) was detected by immunoenzymatic method in 24 h culture medium, and the values are expressed as fold-increase over the
control values. (E) RANKL/OPG ratio was obtained by the expression values measured with western blots. The data are the mean  SEM
of four independent experiments. *P ≤ 0.05 compared to the respective C values; ○P ≤ 0.05 and ○○P ≤ 0.005 compared to the respective S
values; □P ≤ 0.005 compared to S values for 4 h and stimulated with 17b-E2.
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Direct involvement of GSTP1-1 in the protective
effect of 17b-E2 and NAC on oxidative stress-induced
apoptosis and on their ability to modulate JNK activa-
tion has been shown by GSTP1-1 down-regulation. In
particular, GSTP1-1 seems important in mediating the
early antiapoptotic effect of estrogen through inhibi-
tion of JNK in the presence of an oxidative state. In
fact, in 17b-E2-treated cells, down-regulation of
GSTP1-1 similarly reverts both apoptosis and JNK
activation to starved cell values. Also in NAC-treated
cells, down-regulation of GSTP1-1 increased both
apoptosis and JNK activation levels, but these do not
return to starved cell values, indicating that stress-
induced JNK activation followed by apoptosis may
also in part depend on other GSTP1-1-independent
redox-regulated factors.
Previously, we demonstrated that when there is an
oxidative state in MLO-Y4 the expression of factors,
such as RANKL, OPG, and sclerostin involved in
bone remodeling, are related to apoptosis as well as to
JNK and ERK1/2 activity [21]. Indeed, these factors
are expressed by osteocytes under various conditions,
including bone pathological alterations [1–
4,7,11,52,53]. RANKL increases osteoclast differentia-
tion and bone resorption, whereas OPG competes with
RANKL for its receptor inhibiting osteoclastogenesis
[2–4,52,53]. Moreover, it has been shown that regula-
tion of the RANKL/OPG ratio is one of the means by
which bone resorption and formation can be main-
tained in equilibrium, and the RANKL/OPG ratio is
indicative of osteoclastogenic activity in various bone
remodeling diseases [1,3,52,53]. Sclerostin (mainly pro-
duced by mature osteocytes) is a negative regulator of
osteoblast activity and OPG production [1–5,53] and it
inhibits the Wnt/beta-catenin signaling pathway pre-
venting OPG production [1–3].
17b-E2 is able to prevent the increased expression
and release of RANKL and the increased expression
of sclerostin. However, 17b-E2 is not able to com-
pletely revert RANKL and sclerostin levels to those of
control, unlike antioxidants which in these cells inhibit
both JNK and ERK1/2 activity [21]. 17b-E2 is also
able to prevent, in part, the remarkable decrease in
OPG levels observed in starved osteocytes, similarly to
antioxidants, as only JNK activity is involved in the
down-regulation of OPG expression [21]. Given that
both estrogen and antioxidants almost totally inhibit
JNK activity, their inability to restore normal levels of
OPG expression can be correlated with the involve-
ment of other JNK- and/or oxidative state-indepen-
dent factors and likely related to starvation. All these
data show that the 17b-E2 effect on expression of the
studied cytokines is mediated by JNK inhibition. 17b-
E2 remarkably decreases RANKL/OPG ratio after
24 h from starvation because only at this time does
17b-E2 significantly increase OPG levels. However,
17b-E2, different from that which occurs with antioxi-
dants, does not revert the ratio values to those of the
control [21] probably because of the inability of estro-
gen to quickly eliminate ROS and to inhibit ERK1/2
activation which affects RANKL expression. All these
data show that the fast effect of 17b-E2 on the expres-
sion of the studied cytokines in the presence of oxida-
tive state depends mainly on GSTP1-1 expression that
affects JNK activity. Thereafter, the regulation of
GSTp1-1/JNK association may be related to estrogen
signaling and RANKL/OPG levels.
These data in osteocytes support the efficacy of
estrogen treatment in postmenopausal women by
decreasing sclerostin and RANKL levels, which result
enhanced in serum during estrogen deficiency [1,2,54].
Indeed, both high levels of RANKL and sclerostin
are implicated in the increased bone resorption
associated with estrogen deficiency and microdamage
[12,19,22,23,52]. The effect of 17b-E2 on the up-regu-
lation of OPG may be related to the down-regulation
of sclerostin expression, and this event may be also
related to the modulation of JNK activity by up-reg-
ulation of Gstp1-1. This agrees with a potential
crosstalk between the Wnt/beta-catenin signaling
pathway and estrogen signaling [3,4,37].
Conclusions
The present work shows, for the first time in MLO-Y4
osteocyte-like cells, that 17b-E2 prevents early stress-
induced osteocyte apoptosis which can occur “in vivo”
in estrogen deficiency by inhibition of JNK activation
due to an increased oxidative state. A novel and
important direct involvement of GSTP1-1 in the 17b-
E2 effect on JNK activation and apoptosis in osteo-
cytes has been demonstrated. 17b-E2 up-regulates
GSTP1-1 expression, contributing to maintain JNK
bound to GSTP1-1 and then to inhibit JNK activity.
Our study also shows that estrogen achieves an effect
similar to NAC that, through oxidative state elimina-
tion, is able to inhibit apoptosis and JNK activity
while maintaining JNK bound to GSTP1-1. In fact,
others have demonstrated that the formation of
GSTP1-1/JNK complex may be regulated by oxidative
state changes and/or GSTP1-1 overexpression. It is
interesting to note that the antiapoptotic effect of 17b-
E2 is not due to a direct and quick antioxidant action.
Indeed, antioxidant activity of estrogen can occur later
through the increased expression of antioxidant
enzymes as other researchers have demonstrated.
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Moreover, this study indicates that 17b-E2 through
JNK inhibition by GSTP1-1 association can decrease
the RANKL/OPG ratio and sclerostin level, factors
related to osteogenesis and bone remodeling.
Overall, the data presented here clarify 17b-E2 action
at molecular level in osteocyte activity on bone remodel-
ing, and identify a possible role of GSTP1-1 and JNK
activity in bone repair mechanisms in pathologies
related to oxidative stress. Finally, they confirm the
validity of antioxidants as therapeutic support.
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In MLO-Y4 osteocytes, 17b-estradiol (17b-E2) prevents starvation-induced apoptosis related to oxidative stress-induced
JNK and osteoclastogenic activation. This occurs by a redox-independent process involving overexpression of GSTP1-1,
which in monomeric form binds JNK, inhibiting its activation. No early antioxidant activity of 17b-E2 has been found.
ROS induces GSTP1-1 polymerization and JNK activation by phosphorylation with consequent osteocyte apoptosis.
